Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients (P11-6.005)

Bradley J. Barney; Skyler Peterson; Michael Waltz; Melissa W. Wright; John Rose; Mary Rensel; Aaron Abrams; Emmanuelle Waubant; Yolanda Wheeler; Moses Rodriguez; Jan‐Mendelt Tillema; Lauren Krupp; Mark Gorman; Leslie Benson; Timothy Lotze; Nikita Shukla; Soe Mar; Tanuja Chitnis; Teri Schreiner; Megan Vignos; Jonathan Planton; T. Charles Casper

doi:10.1212/wnl.0000000000206450

Abstract

Summarize the demographic/clinical characteristics and efficacy outcomes of individuals with pediatric-onset multiple sclerosis (POMS) who were treated with Avonex or Plegridy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Barney et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678197 https://doi.org/10.1212/wnl.0000000000206450

View at Publisher

Ask AI

Bookmark

Share

Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients (P11-6.005)

Abstract

Discussion

Cite This Study

Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients (P11-6.005)

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology